News

03

Aug
Ever since generic DAA made available in early 2015 with Gilead's VL to several Indian generic manufacturers, there has been some progress as well as challenges in the context of access to Hepatitis C treatment. During Asia Pacific AIDS and Co-infection conference in Hong Kong June 2017, Giten Khwahirakpam from ...

15

Feb
A joint press release between I-MAK, DNP+ and MSF Access Campaign on challenges to patents (patent oppositions) was filed in India on key hep C drugs sofosbuvir, daclatasvir and velpatasvir. New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India ...

29

Mar
For pricing and availability of generic Indian daclatasvir as on 7 March 2016, Please click here.

08

Mar
For a simplified snapshot from TREAT Asia/amfAR on ledipasvir and sofosbuvir co-formulation for the treatment of hepatitis C, please click here.